Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lee's Pharmaceutical HoldingsLPCUF 75 EV-to-EBIT is 7.21 as of Aug. 29, 2026, which is 41% below its 10-year median of 12.23. GuruFocus rates LPCUF with a GF Score™ of 75/100 and a GF Value™ of $0.24. The stock has 5 warning signs investors should review. Among 691 Drug Manufacturers companies, Lee's Pharmaceutical Holdings ranks better than 87.26% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lee's Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was $88.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings EV-to-EBIT Related Terms
Lee's Pharmaceutical Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's EV-to-EBIT falls into.
Lee's Pharmaceutical Holdings's current Enterprise Value is $77.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (LPCUF) has a EV-to-EBIT of 7.21 as of Aug. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 41% below median its historical median of 12.23. Over the past decade, Lee's Pharmaceutical Holdings' EV-to-EBIT has ranged from 0.37 to 29.19. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #88 out of 691 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Lee's Pharmaceutical Holdings' EV-to-EBIT too high?
Lee's Pharmaceutical Holdings' current EV-to-EBIT of 7.21 is 41% below median its 10-year median of 12.23. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 29.19. The Drug Manufacturers industry median EV-to-EBIT is 15.71. Lee's Pharmaceutical Holdings' value of 7.21 is 54.1% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #88 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #88 out of 691 companies for EV-to-EBIT. This places Lee's Pharmaceutical Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.71. Lee's Pharmaceutical Holdings' value of 7.21 is 54.1% below this benchmark. Historically, Lee's Pharmaceutical Holdings' own EV-to-EBIT has ranged from 0.37 to 29.19 over the past decade. While the company's 10-year median is 12.23 vs. the industry median of 15.71, Lee's Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current EV-to-EBIT of 7.21 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current EV-to-EBIT is 7.21, which is 41% below median its own 10-year median of 12.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current EV-to-EBIT of 7.21. The stock's GF Value™ is $0.24, compared to a current price of $0.19 — trading 20.7% below its estimated fair value. The current EV-to-EBIT is 7.21, which is 41% below median its 10-year median of 12.23 and 54.1% below the Drug Manufacturers industry median of 15.71. Lee's Pharmaceutical Holdings' overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current EV-to-EBIT is 7.21 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of $0.19 is trading 20.7% below its estimated GF Value™ of $0.24.
Key valuation signals for LPCUF:
EV-to-EBIT: 7.21 (41% below median its 10-year median of 12.23)
GF Value™: $0.24 vs. price of $0.19 (20.7% below fair value)
Industry Position: 54.1% below the Drug Manufacturers median (#88 of 691)
No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
75GF Score
Get the complete analysis for LPCUF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCUF has been successfully added to your 
